Biogen

Youtube Subscribe

Open: 313.5 Close: 310.12 Change: -3.38

The top 15 things about Biogen Company Inc found by an AI.

How much time have you spent trying to decide whether investing in Biogen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, price, …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Biogen stock was originally listed at a price of $5.73 in Dec 31, 1997. Biogen-Idec is a company based in Ireland and focuses on neurology, immunology, and hemophilia.

Today's News

Biogen chalks up a tecfidera patent win in europe after losing us protections. Biogen and Eisai reported the finding from a large late-stage clinical trial. B of A Securities has decided to maintain their Neutral rating on Biogen, which currently sits at a price target of $320. Guggenheim upgraded its action to Buy with a price Target of $350. Needham has. decided to. maintain their Buy rating on. Biogen. investors will be pleased with their favorable 64% return over the last year. Biogen-Idec is a company based in Ireland and focuses on neurology, immunology, and hemophilia. The Healthcare Technology Report announced the Top 25 Women Leaders in Biotechnology. Biogen has partnered with Ionis in developing antisense therapy that blocks the SMA gene. Biogen believes there is sufficient evidence to show that that. blocks the. SMA. gene tofersen, an antisense. therapy, in the spring of 2022, Biogen made decision to pursue accelerated approval. Biogen wins accelerated FDA approval for treatment for rare form of ALS. VA to be First Major Insurer to cover Alzheimers drug Leqembi. Biogen Inc. (BIIB) NASDAQ: BIIB · IEX Real-Time Price · USD Add to Watchlist 310.80 -2.46 (-0.79%) May 11, 2023, Market open at 1:59 PM EDT - Market open. Biogen stock was originally listed at a price of $5.73 in Dec 31, 1997. Biogen secures priority review for alotech drug that failed phase 3 of 3 that failed to be approved for ALS drug.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

Are looking for the most relevant information about Biogen? Investor spend a lot of time searching for information to make investment decisions in Biogen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, price, drug, decide, maintain, rating, Buy, and the most common words in the summary are: biogen, stock, market, report, price, option, biib, . One of the sentences in the summary was: Biogen stock was originally listed at a price of $5.73 in Dec 31, 1997. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #stock #market #report #price #option #biib.

Read more →

Youtube Subscribe

---